Verve Therapeutics, Inc. (VERV)

6.00 -0.01 (-0.17%) At close: 04:00PM EDT

Verve Therapeutics, Inc.

201 Brookline Avenue
Suite 601
Cambridge, MA 02215
United States
617 603 0070
https://www.vervetx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 255

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sekar Kathiresan M.D.	Co-Founder, CEO & Director	973.25k	N/A	1973
Ms. Joan Nickerson M.B.A.	Chief Administrative Officer	N/A	N/A	1969
Ms. Jennifer Robinson	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Kaitlin Duffy	Executive Director of Human Resources	N/A	N/A	N/A
Mr. Yasser M. El-Gamal J.D.	Senior VP of Legal Affairs & Chief Intellectual Property Counsel	N/A	N/A	1968
Mr. Jason Politi	Chief Technical Operations Officer	N/A	N/A	1977
Dr. Troy Lister Ph.D.	Senior Vice President of Research & Early Development	N/A	N/A	N/A
Dr. Leslie Stolz Ph.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Ms. Jaime Kirk	Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Verve Therapeutics, Inc.’s ISS governance QualityScore as of 29 April 2024 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.